Beijing Strong Biotechnologies, Inc.
Shenzhen Stock Exchange 300406.SZ
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio for the year ending December 31, 2023: 0.30
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio is 0.30 for the year ending December 31, 2023, a -9.85% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
-
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio for the year ending December 31, 2022 was 0.34, a -13.85% change year over year.
-
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio for the year ending December 31, 2021 was 0.39, a 316.81% change year over year.
-
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio for the year ending December 31, 2020 was 0.09, a 105.95% change year over year.
-
Beijing Strong Biotechnologies, Inc. Debt to Equity Ratio for the year ending December 31, 2019 was 0.05, a 21.24% change year over year.
Key data
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
Shenzhen Stock Exchange: 300406.SZ
| CEO | Mr. Xi Liu |
| IPO Date | Oct. 30, 2014 |
| Location | China |
| Headquarters | Kuang Yi Building |
| Employees | 1,094 |
| Sector | Healthcare |
| Industries | |
Description
Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
Key trends
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email